Condition: Focal Epilepsy · Epilepsy · Refractory Focal Epilepsy · Sponsor: Rapport Therapeutics Inc.
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
This description comes directly from the study's public registry record.
Daniela Moreno · (857) 323-9048 · dmoreno@rapportrx.com
Beth Bowers · (857) 323-9048 · bbowers@rapportrx.com
Always discuss trial participation with your own doctor first.
| Consultants in Epilepsy and Neurology, PLLC | Boise, Idaho, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| NYU Langone Comprehensive Epilepsy Center | New York, New York, United States | Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| University of Pennsylvania - Department of Neurology | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07219407